Similar to baseline, there was no difference in the levels of EPA, DHA or ARA between APOE3 and APOE4 groups after 12 months of n-3 PUFA supplementation (Figures 2A–C), which is consistent with previous n-3 PUFA intervention studies carried out in healthy subjects (47, 48) and after 18 months of DHA supplementation in patients with Alzheimer's disease (49). This evidence concerns the gene APOE and Alzheimer disease.